Advertisement

Clinical Evaluation of Drug Candidates

  • Scott A. Reines
  • Dick Fong

Abstract

The clinical evaluation of a new chemical entity as a therapeutic agent, and its registration for use as a new drug, are very complex procedures. More than 10 years of research and approximately $65 million may be required from the time of original identification or synthesis of a compound to its commercial introduction as a marketed drug. The majority of the time and money are usually spent on clinical development.

Keywords

Drug Candidate Test Drug Case Report Form Timolol Maleate Drug Regulatory Agency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anello, C. (1974) Considerations of Significance—Clinical and Statistical, in Principles and Techniques of Human Research and Therapeutics vol. IV ( McMahon, F. G., ed.) Futura, Mt. Kisco, New York.Google Scholar
  2. Bakke, O. M., Wardell, W. M., and Lasagna, L. (1984) Drug discontinuations in the United Kingdom and the United States, 1964 to 1983; Issue of safety. Clin. Pharmacol. Ther. 35 (5), 559–567.PubMedCrossRefGoogle Scholar
  3. Berglin. P. (1985) Personal communication.Google Scholar
  4. Bezold, C. (1981) The Future of Pharmaceuticals Wiley, New York.Google Scholar
  5. Cato, A. E. and Cook, L. (1984) The Protocol and Case Report Form, in The Clinical Research Process in the Pharmaceutical Industry ( Matorem, C. M., ed.) Marcel Dekker, New York.Google Scholar
  6. Code of Federal Regulations (1977) 21 (52) Proposed in Federal Register, pp. 49612–49630.Google Scholar
  7. Code of Federal Regulations (1981) 21 (56).Google Scholar
  8. Federal Register (1981) 46 (17). p. 8950.Google Scholar
  9. Federal Register (1985) 50 (36), New Drug and Antibiotic Regulations.Google Scholar
  10. Finkel, M.J. (1984) Role of the FDA in the Clinical Research Process, in The Clinical Research Process in the Pharmaceutical Industry ( Matoren, G. M., ed.) Marcel Dekker, New York.Google Scholar
  11. Friedman, L. M., Feinberg, C. D., and DeMets, D. L. (1984) Fundamentals of Clinical Trials, John Wright PSG, Littleton, Massachusetts.Google Scholar
  12. General Considerations for the Clinical Evaluation of Drugs (1978) US Dept. of Health, Education and Welfare, Public Health Service, Food and Drug Administration.Google Scholar
  13. Haegerstram, G., Huitfeldt, B.S. Nilsson, Sjovall, J., Syvalahti, E., and Whalen, A. (1982) Placebo in Clinical Drug Trials-a Multi- disciplinary Review, Meth. Find. Exp. Clin. Pharmacol 4 (4), 261–278.Google Scholar
  14. Hodges, R. (1974) Ethical Considerations in Clinical Research, Techniques of Human Research and Therapeutics vol. 1 ( McMahon, F. G., ed.) Futura Publishing, Mt. Kisco, New York.Google Scholar
  15. Holie, P. G. (1983) Johnson & Johnson: New Woe, NY Times.Google Scholar
  16. Idanpaan-Heikkila, J. (1983) A Review of Safety Information Obtained from Phases I-II and Phase III Clinical Investigations of Sixteen Selected Drugs. US Dept of Health, Education and Welfare, Public Health Service, Food and Drug Administration.Google Scholar
  17. Inman, W. H. H. (1981) Post-Marketing Drug Surveillance, in Risk-Benefit Analysis in Drug Research ( Cavalla, J. F., ed.) MTP, Lancaster, England.Google Scholar
  18. Legrain, M. (1983) New Drug Superiority, in Decision Making in Drug Research (Gross, F., ed.) Raven, New York.Google Scholar
  19. Matoren, G. M., ed. (1984) The Clinical Research Process in the Pharmaceutical Industry Marcel Dekker, New York.Google Scholar
  20. McGee, D. and Gordon, T. (1976) in The Framingham Study: an Epidemiological Investigation of Cardiovascular Disease Publication No. (NIH) 76 - 1083, US Dept. of Health, Education, and Welfare, Washington, DC.Google Scholar
  21. New Drug and Antibiotic Regulations (1985) in Federal Register 50 (36), pp. 7452–7519, Proposed rules will change the name of the IND to “Investigational New Drug Application.”Google Scholar
  22. Public Law (1962) No. 87-781 (76 Stat. 780).Google Scholar
  23. Schor, S. (1974) Relevant Considerations to the Statistical Analysis of Clinical Data, in Principles and Techniques of Human Research and Therapeutics vol. IV ( McMahon, F. G., ed.) Futura, Mt. Kisco, New York.Google Scholar
  24. Shapiro, M. F. and Charrow. R. P. (1985) Special report: Scientific misconduct in investigational drug trials. N. Eng. J. Med. 312 (11), 731–736.CrossRefGoogle Scholar
  25. Sheck, L., Cox, C., Davis, H.T., Trimble, A. G., Wardell, W. M., and Hansen, R. (1984) Success rates in the United States drug development systems. Clin. Pharmacol. Ther. 36 (5), 574–583.PubMedCrossRefGoogle Scholar
  26. Sher, S. P., Bokelman, D. L., and Ditzler, W. D. (1980) Preclinical toxicity requirements for human drugs. Drug Inforn. J. April/June, 82–97.Google Scholar
  27. Smithells, R. W. (1962) Thalidomide and malformations in Liverpool. Lancet i, 1270–1273.Google Scholar
  28. Spilker, B. (1984) Guide to Clinical Studies and Developing Protocols, Raven, New York.Google Scholar
  29. Sommerville, J. M., McLaren, E. H., Campbell, L. M., and Watson,J. M. (1982) Severe headache and disturbed liver function during treatment with zimelidine. Brit. Med. J. 285, 1009.CrossRefGoogle Scholar
  30. Stellar, S„ Ahrens, S. P., Meibohm, A. R., and Reines, S. A. (1984) Migraine prevention with timolol. J. Am. Med. Assoc. 252 (18), 2576–2580.CrossRefGoogle Scholar
  31. Tillman, C. R. and Koltz, B. E. (1981) Update on hepatotoxic drugs. Hospital Formulary 16, 847–852.Google Scholar
  32. World Medical Assembly (1964) 18th, Helsinki, Finland, as revised by the 29th World Medical Assembly, Tokyo, Japan, 1975.Google Scholar

Copyright information

© The Humana Press Inc. 1987

Authors and Affiliations

  • Scott A. Reines
  • Dick Fong

There are no affiliations available

Personalised recommendations